FLuticasone in cOvid Treatment (FLOT)

Phase 2

• Conditions: Covid19
• Interventions: Drug: Fluticasone Propionate

• Registration Number: NCT05054322
• Lead Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City

Brief Summary

A multicenter, open-label, randomized controlled trial to evaluate the efficacy of fluticasone propionate (metered dose inhaler - MDI) added to standard care at early stage of COVID-19 in reducing the incidence of adverse outcomes (any of those following: oxygen therapy, systemic corticosteroids, hospitalization, mechanical ventilation, and mortality) in symptomatic patients either from 18 to 49 years of age with risk factors or older than 50 years.

Detailed Description

This study has 2 arms: the standard care group followed the COVID-19 guidelines of the Ministry of Health of Vietnam and the interventional group: Fluticasone propionate MDI with spacer, twice a day for 14 days.

The study participants will be monitored via video call from day 1 to day 14, day 21, and day 28 after randomized.

Study Timeline

• Status Verified: 2021-09
• Study First Submitted: 2021-09-20
• Study First Submitted QC: 2021-09-21
• Last Update Submitted: 2021-09-21
• Study Start: 2021-09-22
• Study First Posted: 2021-09-23
• Last Update Posted: 2021-09-23
• Primary Completion: 2022-01-31
• Study Completion: 2022-08-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Signing consent to participate in the study
2. Having COVID related-symptoms within 5 days prior to randomization
3. Confirmed diagnosis of COVID-19 by rapid antigen test or polymerase chain reaction (PCR) test within 5 days prior to randomization
4. Over 50 years old OR 18-49 years old and have one or more of risk factors for severe COVID-19

Exclusion Criteria

1. Pregnant or breastfeeding woman
2. Allergy and/or contraindications to inhaled Fluticasone
3. Current or previous administration of inhaled corticosteroids within the 15 days prior to randomization
4. Current or previous administration of high dose systemic corticosteroids (higher than 3.75 mg dexamethasone/day or equivalent doses of other corticosteroids) and/or anticoagulants etc.. more than or equal to 2 days within 15 days prior randomization, or taking any other antiviral drugs (such as remdesivir, favipiravir, etc..)
5. Indication for start of systemic corticosteroids or oxygen therapy or hospitalization dut to COVID-19 within next 24 hours
6. Already participated in other interventional COVID studies
7. Any conditions for which the investigator believes that the patient should not participate for the benefit of the patient or that would prevent, limit, or distort the evaluation of the study procedure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Fluticasone propionate with spacer	Fluticasone Propionate	Fluticasone propionate 125 mcg with spacer, 4 puffs, twice a day, added to standard care

Primary Outcome Measures

Name	Time	Method
Incidence of adverse outcomes	Day 28 after randomization	To evaluate the efficacy of fluticasone propionate MDI added to standard care at an early stage COVID-19 in reducing the incidence of adverse outcomes (oxygen therapy, systemic corticosteroids, hospitalization, mechanical ventilation, and mortality) in symptomatic patients either from 18 to 49-year-old with risk factors or older than 50-year-old.

Secondary Outcome Measures

Name	Time	Method
Duration of isolation based on WHO's criteria	Day 28 after randomization	To evaluate the efficacy of fluticasone propionate MDI added to standard care at early stage COVID-19 in reducing duration of isolation bases on WHO's criteria in symptomatic patients either from 18 to 49-year-old with risk factors or older than 50-year-old
The incidence of patients with oxygen saturation by pulse oximetry (SpO2) <94%	Day 28 after randomization	To evaluate the efficacy of fluticasone propionate MDI added to standard care at an early stage COVID-19 in reducing the incidence of patients with SpO2\<94% in those either from 18 to 49-year-old with risk factors or older than 50-year-old
Self-reported recovery rate	Day 28 after randomization	To evaluate the efficacy of fluticasone propionate MDI added to standard care at an early stage COVID-19 in reducing self-reported recovery rate of symptomatic patients either from 18 to 49-year-old with risk factors or older than 50-year-old

Trial Locations

Locations (1)

University of Medicine and Pharmacy at Ho Chi Minh City; 🇻🇳 Ho Chi Minh City, Vietnam